SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report

• Published in: Journal for immunotherapy of cancer Vol. 11; no. 1; p. e005957
• Main Authors: McNerney, Kevin Owen, Richards, Rebecca M, Aguayo-Hiraldo, Paibel, Calkoen, Friso G, Talano, Julie-An, Moskop, Amy, Balduzzi, Adriana, Krajewski, Jennifer, Dave, Hema, Vatsayan, Anant, Callahan, Colleen, Liu, Hongyan, Li, Yimei, Davis, Kara Lynn, Maude, Shannon L
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group Ltd 01.01.2023; BMJ Publishing Group LTD; BMJ Publishing Group
• Series: Original research
• Subjects: Adolescent; Adult; Antigens; Asymptomatic; Betacoronavirus; Blood cancer; Cancer; Cancer therapies; Cell- and Tissue-Based Therapy; Chemotherapy; Child; Clinical/Translational Cancer Immunotherapy; Coronavirus Infections - complications; Coronaviruses; COVID-19; COVID-19 - complications; COVID-19 vaccines; Hematologic Neoplasms; Hematology; Hospitalization; Humans; Hypertension; Immunization; Immunotherapy; Infections; Intensive care; Leukemia; Lymphoma; Medical laboratories; Multisystem inflammatory syndrome in children; Neoplasm Recurrence, Local; Oncology; Patients; Pediatrics; Pneumonia, Viral - complications; Receptors, Chimeric Antigen; Registries; Remission (Medicine); Retrospective Studies; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Stem cell transplantation; Ventilators; Young Adult; Young adults; United States > US; COVID-19; Receptors, Chimeric Antigen; Pediatrics; Hematologic Neoplasms; Immunotherapy

BackgroundImmunocompromised patients are at increased risk of SARS-CoV-2 infections. Patients undergoing chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory B-cell malignancies are uniquely immunosuppressed due to CAR T-mediated B-cell aplasia (BCA). While SARS-CoV-2 mortality rat...